Abstract
Posterior polymorphous corneal dystrophy (PPCD) is a rare autosomal dominant genetically heterogeneous disorder. Nineteen Czech PPCD pedigrees with 113 affected family members were identified, and 17 of these kindreds were genotyped for markers on chromosome 20p12.1- 20q12. Comparison of haplotypes in 81 affected members, 20 unaffected first degree relatives and 13 spouses, as well as 55 unrelated controls, supported the hypothesis of a shared ancestor in 12 families originating from one geographic location. In 38 affected individuals from nine of these pedigrees, a common haplotype was observed between D20S48 and D20S107 spanning approximately 23 Mb, demonstrating segregation of disease with the PPCD1 locus. This haplotype was not detected in 110 ethnically matched control chromosomes. Within the common founder haplotype, a core mini-haplotype was detected for D20S605, D20S182 and M189K2 in all 67 affected members from families 1–12, however alleles representing the core mini-haplotype were also detected in population matched controls. The most likely location of the responsible gene within the disease interval, and estimated mutational age, were inferred by linkage disequilibrium mapping (DMLE+2.3). The appearance of a disease-causing mutation was dated between 64–133 generations. The inferred ancestral locus carrying a PPCD1 disease-causing variant within the disease interval spans 60 Kb on 20p11.23, which contains a single known protein coding gene, ZNF133. However, direct sequence analysis of coding and untranslated exons did not reveal a potential pathogenic mutation. Microdeletion or duplication was also excluded by comparative genomic hybridization using a dense chromosome 20 specific array. Geographical origin, haplotype and statistical analysis suggest that in 14 unrelated families an as yet undiscovered mutation on 20p11.23 was inherited from a common ancestor. Prevalence of PPCD in the Czech Republic appears to be the highest worldwide and our data suggests that at least one other novel locus for PPCD also exists.
Introduction
Posterior polymorphous corneal dystrophy (PPCD) is a rare bilateral disorder transmitted as an autosomal dominant trait. Clinically PPCD is characterized by vesicles, bands and polymorphous opacities with pathology at the level of Descemet membrane and the corneal endothelium. Peripheral anterior iris adhesions, iris atrophy, pupillary ectropion and corectopia may also develop. Occasional severe visual disability results from secondary glaucoma or corneal edema [1]–[3]. On ultrastructural examination, corneal endothelial cells show fibroblastic and epithelial-like transformation [4]–[7].
The genetic heterogeneity of PPCD is currently known to be represented by three loci on chromosomes 20, 1, and 10 [8]–[11]. PPCD1 (MIM ID #122000) is located on 20p11.21. Mutation of the visual system homeobox gene 1 (VSX1; MIM ID #605020) within this locus was reported as disease-causing in a few PPCD cases [12], [13]. PPCD2 (MIM ID #609140) is caused by mutation of the alpha-2 chain of type VIII collagen gene (COL8A2; MIM ID #120252) located on 1p34.3-p32.3, however only one disease-causing mutation in one family has been described to date [9]. Mutations in the zinc finger E-box binding homeobox 1 gene (ZEB1; MIM ID #189909) mapping to chromosome 10p11.2 were identified as disease-causing in PPCD3 (MIM ID #609141) and it has been estimated that pathogenic changes within this gene account for approximately 25% of all PPCD cases, with a range from 9%–45% depending on population studied [14]–[16]. We have previously shown that in two Czech families PPCD is linked to the short arm of chromosome 20, flanked by the markers D20S48 and D20S139 [11]. Exclusion of VSX1 from this genetic interval by a linkage study, and lack of disease-causing changes, implies that an as yet undiscovered gene is causative for PPCD1 [11].
Families affected by rare dominantly inherited disorders are often unrelated, however occasionally they share a chromosomal genomic region implying that the pathogenic mutation arose in a common ancestor [17].
In this study we observed that PPCD in the Czech Republic appears to have a remarkably high prevalence. A total of 19 Czech PPCD families, including two previously linked pedigrees [11], were ascertained and members of 17 pedigrees were genotyped for microsatellite markers spanning a region from 20p12.1 to 20q12. We correlated the observed haplotypes with geographical origin of the eldest family member known to suffer from the disorder and demonstrate that the high prevalence of PPCD in the Czech Republic is due to a common founder.
Materials and Methods
Patients
The study was approved by the Ethics Committee of General University Hospital in Prague, Czech Republic and conformed to the tenets of the Declaration of Helsinki. All participants signed an informed consent prior to inclusion into the study.
Subjects from 19 Czech pedigrees with familial PPCD were examined between the years 1995–2010 in the Department of Ophthalmology of the First Faculty of Medicine, Charles University in Prague. Ophthalmologic assessment included visual acuity, slit lamp examination, intraocular pressure measurements and specular microscopy using Noncon ROBO Pachy SP-9000 (Konan Medical Inc, Tokyo). Diagnosis of PPCD was based on positive family history and the presence of vesicles and polymorphic opacities at the level of Descemet membrane and the corneal endothelium. Pedigrees were drawn and residency within the Czech Republic of the eldest family member known to suffer from PPCD was noted. Geographic origin of the families was plotted on a map.
Genotyping and Haplotype Analysis
DNA was isolated from venous blood samples using the Nucleon III BACC3 genomic DNA extraction kit according to manufacturer’s instructions (GE Healthcare, UK). Genotyping was performed using 11 polymorphic microsatellite markers on chromosome 20 which were fluorescently labeled and amplified by polymerase chain reaction (PCR). Ten microsatellites were commercially available: D20S98, D20S118, D20S114, D20S48, D20S605, D20S182, D20S139, D20S190, D20S106 and D20S107 (Invitrogen, Paisley, UK). A dinucleotide marker used in this study, M189K21, was reported previously [11]. Amplification was performed in 25 µl reaction volumes. Markers were run on an ABI 3100 and analyzed using Genescan and Genotyper software (Applied Biosystems, Foster City, CA).
To investigate the possibility of a common lineage, haplotypes of affected individuals were constructed based on segregation within the families, and then compared between families. In order to calculate allele frequencies and haplotype frequencies in the population, 55 unrelated Czech population matched controls (110 chromosomes) were also genotyped for each marker.
Analysis of the Disease Gene Location and Age of the Mutation
To infer the location of a gene responsible for PPCD1 in the population studied and to estimate the age of the mutation (i.e. the time elapsed since the appearance of the common ancestor in the population) DMLE+ (Disease Mapping using Linkage disequilibrium) version 2.3 (www.dmle.org) was used. The program DMLE+ uses Bayesian estimates of the location of a gene with a mutation affecting a discrete (disease) trait based on the observed linkage disequilibrium at multiple genetic markers. Other parameters are also estimated, such as mutation age [18], [19].
Input for this analysis was the common PPCD genotypes of affected individuals originating from the same geographic location, and the haplotypes of population matched control individuals. Prior to DMLE+2.3 analysis, haplotypes of unrelated controls were predicted using the PHASE program [20], [21]. Genetic distances of individual markers used in the analysis were taken from the Marshfield genetic map (http://research.marshfieldclinic.org/genetics/GeneticResearch/compMaps.asp). For markers which do not appear on this genetic map (D20S98, D20S48, M189K21, D20S139) the distance in cM was estimated empirically by interpolation using the standard curve of physical distance. Since DMLE+2.3 does not accept identical distances for more than one marker, where the position of two markers obtained from the Marshfield genetic map was identical (i.e. D20S118, D20S114, D20S605, D20S182) position was recalculated using the standard curve as above (see Supporting Information Table S1). The following variable values were used in the DMLE+2.3 analysis: population growth rate of 0.95. This was calculated from an estimated population size of 100,000 inhabitants 2000 years ago and current population size of 6,700,000 inhabitants living in the historic regions of Bohemia that have been historically compact. The estimated frequency of the disease in the population was set at 0.001.
Screening the ZNF133 Gene
Two probands from families 1 and 2, previously shown to be linked to 20p11.2 [11], as well as one unaffected first-degree relative from family 2 were screened. Amplification was carried out in a 25 µl reaction containing 12.5 µl of ReddyMixTM PCR master mix (ABgene Limited, Epsom, UK), with 50 pmoles gene-specific primers (see Supporting Information Table S2) and approximately 50 ng of genomic DNA. The PCR amplicons were purified and sequenced on both strands as previously described [22]. Nucleotide sequences were compared with the published zinc finger protein 133 (ZNF133; MIM ID #604075) reference sequence (NM_003434 and NM_001083330). Both coding and untranslated regions as well as intron-exon boundaries were screened.
Comparative Genomic Hybridisation
Array comparative genomic analysis (CGH) was used to evaluate DNA copy number variation (CNV) on chromosome 20 (NimbleGen, Berlin, Germany) with a median probe spacing of 134 bp. Patient DNA from family 1, previously shown to be linked to 20p11.2 [11], was labeled with Cy-3 and a reference sex matched DNA sample was labeled with Cy5. Array construction, labeling, hybridisation, and normalisation were performed by NimbleGen. The data were visualised and analysed using SignalMap software (NimbleGen).
Results
Clinical ascertainment demonstrated bilateral corneal changes consistent with the diagnosis of PPCD in 113 subjects (48 males, 65 females) from 19 families. None of the PPCD families were known to be related to one another. In all families PPCD was consistent with autosomal dominant inheritance pattern, with incomplete penetrance noted for family 18 and 19 [23]. Of these, 32 patients were from two large pedigrees (families 1 and 2) previously linked to the short arm of chromosome 20 [11]. Families 1–14 originated from the western or southwestern part of the Czech Republic, 12 of which were from a small region of approximately 13 km radius around the town of Klatovy (Figure 1) with an estimated current population of 30,000 inhabitants. Out of the 19 families identified, 81 affected individuals from 17 families were genotyped, including members of the two families in which linkage analysis was previously performed [11]. Table 1 summarizes the number of individuals genotyped for each family, their clinical status, molecular genetic findings and geographical origin within the Czech Republic.
Table 1. Summary of posterior polymorphous corneal dystrophy study families and subjects.
Family | Examinedaffected | Genotypedaffected | Genotyped unaffected | Genotypedspouses | Incomplete penetrance | Number of affected individuals with common haplotype on 20p12.1- 20q12/core mini-haplotype | Geographical origin |
1 | 15 | 14 | 7 | 5 | N | 10/14 | Southwest |
2 | 16 | 14 | 6 | 5 | N | 6/14 | Southwest |
3 | 8 | 7 | 0 | 1 | N | 6/7 | Southwest |
4 | 5 | 5 | 1 | 0 | N | 2/5 | Southwest |
5 | 10 | 7 | 2 | 1 | N | 6/7 | West |
6 | 9 | 6 | 2 | 0 | N | 2/6 | Southwest |
7 | 4 | 4 | 0 | 0 | N | 3/4 | Southwest |
8 | 5 | 4 | 0 | 0 | N | 2/4 | Southwest |
9 | 3 | 2 | 0 | 0 | N | 0/2 | Southwest |
10 | 2 | 2 | 0 | 0 | N | 0/2 | Southwest |
11 | 2 | 1 | 1 | 0 | N | 0/1 | Southwest |
12 | 1 | 1 | 0 | 0 | N | 1/1 | Southwest |
13 | 6 | 0 | 0 | 0 | N | Not performed | Southwest |
14 | 2 | 0 | 0 | 0 | N | Not performed | Southwest |
15 | 16 | 7 | 1 | 0 | N | 0/0 | Central |
(Segregation with 20p12.1- 20q12 excluded byhaplotype analysis) | |||||||
No mutation in VSX1, COL8A2 or ZEB1 | |||||||
16 | 2 | 2 | 0 | 0 | N | 0/0 | Northeast |
No mutation in VSX1, COL8A2 or ZEB1 | |||||||
17 | 3 | 1 | 0 | 0 | N | 0/0 | East |
No mutation in VSX1, COL8A2 or ZEB1 | |||||||
18 | 3 | 3 | 0 | 1 | Y | ZEB1 mutation identified | North |
No mutation in VSX1 or COL8A2 | |||||||
19 | 1 | 1 | 0 | 0 | Y | ZEB1 mutation identified | Central |
No mutation in VSX1 or COL8A2 | |||||||
Total | 113 | 81 | 20 | 13 |
Number of phenotyped and genotyped affected family members, unaffected first degree relatives and spouses included in this study. Presence of shared haplotype across 20p12.1- 20q12 spanning over 23 Mb as well as the core mini-haplotype at 20p12.1-20p11.23 in affected individuals, previous molecular genetic analysis and geographical origin within the Czech Republic of the eldest family member known to be affected is also shown.
N = No, Y = yes.
Analysis of genetic markers on 20p12.1- 20q12 revealed a common haplotype spanning a region of at least 23 Mb surrounding the centromere and encompassing both the short and long arm of chromosome 20. This full common haplotype was detected in 16 affected members of the two previously linked PPCD1 families (1 and 2) and also in 22 affected members from families 3–8 and 12 (see Supporting Information Table S3). None of the 55 population matched controls had a combination of markers that would allow for reconstruction of this full haplotype. The founder haplotype segregated with disease in families with more than one genotyped affected individual. In all 67 affected members from families 1–12 a core shared mini-haplotype was detected for D20S605, D20S182 and M189K2. The boundary of this haplotype was defined by recombinations with flanking markers D20S48 and D20S139 as less than 2.4 Mb (see Supporting Information Table S3). However, alleles representing this mini-haplotype were also found in 12 controls out of 55.
In families 15–19, analysis did not reveal the common shared haplotype detected in families clustered from the southwest part of the Czech Republic. In family 15, segregation of genotyped markers on 20p12.1-20q12 with PPCD was not observed suggesting they are not linked to this locus. In family 16, only two affected family members were genotyped and in families 17 and 19 only the proband was available for genotyping, thus assessment of haplotype segregation with disease could not be reliably performed (see Supporting Information Table S3).
Analysis of the haplotypes using DMLE+2.3 yielded an estimate that families 1–12 had a common ancestor originating between 64–133 generations ago, with maximum posterior probability at 90 generations; i.e. 1800 years assuming a 20-year generation time or 2250 years with a 25-year generation time (Figure 2). The mutation locator identified the potential locus harboring the ancestral disease-causing change between D20S182 and M189K21 (Figure 3) with 95% confidence. This interval corresponds to a physical distance of only 60 Kb which contains one known protein coding gene; ZNF133.
The ZNF133 gene was therefore screened by direct sequencing for a mutation in probands from two Czech PPCD1 families (1 and 2), however no potential pathogenic changes in the annotated coding and untranslated regions were identified. Since a deletion or duplication of the ZNF133 gene would not be detected by PCR amplification and sequencing, we also performed dense chromosome 20 CGH analysis (Nimblegen) to detect any CNVs in an affected individual from family 1. No microdeletions or duplications on 20p12.1-20p11.23 were detected in this patient.
Discussion
Identification of 113 affected individuals from 19 Czech PPCD families demonstrates, to the best of our knowledge, the highest reported prevalence of PPCD worldwide. Correlated to the population, at least 1 in 100,000 inhabitants in the Czech Republic are affected with PPCD. Because of the relative rarity of this disorder, a founder effect was suspected as the most likely explanation.
In this study we show that 38 affected individuals from nine families, including two previously reported families [11], who originate from a particular region within the Czech Republic display a common disease-associated haplotype across a region of at least 23 Mb on chromosome 20. This particular combination of marker alleles was not detected in any of the 55 ethnically matched controls (110 chromosomes) and is therefore markedly over-represented in Czech PPCD families. In addition, 29 affected individuals from 12 families display only part of the disease-associated haplotype, however corroboration of regional clustering also supports the hypothesis that they are descendants of the same ancestor. In two families (13 and 14) affected individuals were not available for genotyping, however because of their geographical origin from the same region as pedigrees 1–12 and the severity of their phenotype, it is likely that they would also share the same common ancestor. Since the information on family origin was based on the eldest member known to clearly suffer from PPCD, we could only trace ancestors back to the last century. Despite the fact that some families originated in nearby villages we were not able to link the pedigrees so they were considered as unrelated for the statistical analyses.
Affected individuals within Czech PPCD1 pedigrees were observed in all subsequent generations implying that the disorder is highly if not fully penetrant, consistent with other studies [8], [24].
Although the fully shared haplotype among members of nine families comprised about 1/3 of chromosome 20 including the centromere and pericentromeric regions, we have calculated that the original mutational event did not occur recently. Since the families originate from one particular geographical area, we assume that they represent a relatively isolated population, which are known to have more extensive linkage disequilibrium than outbred populations [25]. In addition, some regions of genomes are less prone to recombination and large regions of linkage disequilibrium have been shown to occur especially around the centromere [26], [27].
The mutation age was estimated to be 1800 years assuming a 20-year generation time. It remains to be elucidated if the disease-causing variant arose in the Czech Republic and is specific for that particular geographical region or if it is an ancient mutation introduced from elsewhere. Once the PPCD1 causing gene is discovered it will be possible to further explore these hypotheses.
The minimal shared region in families 1–12 was observed between D20S48 and D20S139, which corresponds to the locus delineation by linkage analysis we described previously in Czech families [11]. Yellore et al. narrowed the proximal boundary of the PPCD1 genetic interval to D20S182 defining the critical disease physical interval to a 1.8 Mb region, under the assumption that there is no micro-heterogeneity [24]. Despite the fact that the PPCD1 locus has been refined to a relatively small interval, the disease-causing gene still remains to be identified even after next-generation sequence analysis of the entire selectively enriched chromosomal region between markers D20S48 and D20S190 [28].
The strongest candidate disease gene based on our current analysis is ZNF133 which is a transcriptional repressor containing KRAB box and zinc finger domains [29] with corneal endothelial expression (http://www.corneanet.net/) [30]. Coupled with the fact that mutations in another zinc finger protein are already known to cause PPCD3 [14] we considered ZNF133 to be the best positional candidate in the refined PPCD1 region, however we did not detect a pathogenic change within currently annotated coding or untranslated regions of this gene. Similarly, no pathogenic variants were observed for ZNF133 in two other studies using probands from different PPCD families linked to chromosome 20 [28], [31]. A CNV or balanced translocation was also considered, however routine karyotype examination in probands from families 1 and 2, and CGH analysis of an affected member of family 1 did not identify any gross or subtle CNVs at this locus. The lack of identification of a pathogenic mutation suggests that if ZNF133 is disease-causing, the change might be located in regulatory sequences, as yet unidentified exons or deep within the introns of this gene.
The data presented here, taken together with previous linkage studies, candidate gene screening, targeted genomic next-generation sequencing [8], [11], [25], [28], [31] and our CGH data excluding a CNV, it is perhaps surprising that the causative mutation/gene has not been identified. Potential for locus micro-heterogeneity may be hindering progress. In addition our current functional knowledge of candidate genes in the interval, including ZNF133, is very limited such that splice variants and important elements controlling transcription remain undefined. The causative mutations may lie in these uncharacterised upstream regions, exons, and introns or within as yet undiscovered genes on 20p12.1-20p11.23. Independent analysis of each family, by targeted next generation sequencing of the disease interval defined by recombinations within a single large linked family, would circumvent any assumption of locus homogeneity, and may represent the most comprehensive approach, if complemented with Sanger sequencing of gaps and gene expression studies.
Families 15–19 apparently originate from different parts of the country than families 1–14 and these families provided an excellent internal control for our analyses. None of these kindreds had the full consensus haplotype and, with the exception of the proband from family 19, they did not share the minimal core haplotype segment found in all 64 affected individuals from pedigrees 1–12. Based on these observations, it is likely that PPCD in these families is caused by a different mutation or a different gene. In support of this, disease-causing mutations in ZEB1 were detected in families 18 and 19 [23]. No mutations in coding regions of any currently known PPCD genes were detected in families 15–17 which suggests that a novel PPCD locus may exist [23] (Table 1).
We conclude that in the Czech population ZEB1 changes account for approximately 4% cases, whereas a disease-causing gene at the 20p12.1-20p11.23 locus is likely to be responsible for more than 80% of all PPCD cases. A recent study by Vincent et al. highlights the fact that in some cohorts ZEB1 accounts for a smaller proportion of cases than originally thought [14]–[16].
Clinical implications of our study lie in the fact that PPCD1 seems to be more severe showing a higher percentage of secondary glaucoma and necessity for keratoplasty than PPCD3, which has a direct impact on patient counseling [32]. Our data suggests that once the PPCD1 gene is identified, it will account for the majority of PPCD in the Czech Republic thus a diagnostic test could be readily developed which would benefit this patient group.
In summary we have demonstrated that the high frequency of PPCD in the Czech Republic is attributable to a founder mutation located on 20p12.1-20p11.23. The disease gene and causative variant have yet to be identified. We anticipate that approximately 80% of PPCD in the Czech population will be attributed to the mutant allele at the locus on chromosome 20p, however it is also clear that other PPCD genes or alleles are implicated as not all families described in this study share a common founder haplotype. Consistent with this finding ZEB1 mutations were previously identified in two families (18, 19), and lack of the PPCD1 haplotype in two families (16, 17) suggests they may not be associated with the PPCD1 locus. In family 15, the PPCD1 locus is excluded and no mutation was detected in VSX1, COL8A2 or ZEB1 suggesting a novel locus may exist.
Supporting Information
Acknowledgments
The authors would like to thank the Demographic Information Centre, Prague, Czech Republic for advice on historic estimates of the Czech population number.
Funding Statement
This work was supported by research grant GACR P301/12/P591. Institutional support was provided by UNCE 204011 and PRVOUK-P24/LF1/3 programs of the Charles University in Prague. AJH is a Faculty member of the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Krachmer JH (1985) Posterior polymorphous corneal dystrophy: a disease characterized by epithelial-like endothelial cells which influence management and prognosis. Trans Am Ophthalmol Soc 83: 413–475. [PMC free article] [PubMed] [Google Scholar]
- 2. Cibis GW, Krachmer JA, Phelps CD, Weingeist TA (1977) The clinical spectrum of posterior polymorphous dystrophy. Arch Ophthalmol 95: 1529–1537. [DOI] [PubMed] [Google Scholar]
- 3. Laganowski HC, Sherrard ES, Muir MG (1991) The posterior corneal surface in posterior polymorphous dystrophy: a specular microscopical study. Cornea 10: 224–232. [DOI] [PubMed] [Google Scholar]
- 4. de Felice GP, Braidotti P, Viale G, Bergamini F, Vinciguerra P (1985) Posterior polymorphous dystrophy of the cornea. An ultrastructural study. Graefes Arch Clin Exp Ophthalmol 223: 265–271. [DOI] [PubMed] [Google Scholar]
- 5. Polack FM, Bourne WM, Forstot SL, Yamaguchi T (1980) Scanning electron microscopy of posterior polymorphous corneal dystrophy. Am J Ophthalmol 89: 575–584. [DOI] [PubMed] [Google Scholar]
- 6. Henriquez AS, Kenyon KR, Dohlman CH, Boruchoff SA, Forstot SL, et al. (1984) Morphologic characteristics of posterior polymorphous dystrophy. A study of nine corneas and review of the literature. Surv Ophthalmol 29: 139–147. [DOI] [PubMed] [Google Scholar]
- 7. Jirsova K, Merjava S, Martincova R, Gwilliam R, Ebenezer ND, et al. (2007) Immunohistochemical characterization of cytokeratins in the abnormal corneal endothelium of posterior polymorphous corneal dystrophy patients. Exp Eye Res 84: 680–686. [DOI] [PubMed] [Google Scholar]
- 8. Heon E, Mathers WD, Alward WL, Weisenthal RW, Sunden SL, et al. (1995) Linkage of posterior polymorphous corneal dystrophy to 20q11. Hum Mol Genet 4: 485–488. [DOI] [PubMed] [Google Scholar]
- 9. Biswas S, Munier FL, Yardley J, Hart-Holden N, Perveen R, et al. (2001) Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum Mol Genet 10: 2415–2423. [DOI] [PubMed] [Google Scholar]
- 10. Shimizu S, Krafchak C, Fuse N, Epstein MP, Schteingart MT, et al. (2004) A locus for posterior polymorphous corneal dystrophy (PPCD3) maps to chromosome 10. Am J Med Genet 130A: 372–377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Gwilliam R, Liskova P, Filipec M, Kmoch S, Jirsova K, et al. (2005) Posterior polymorphous corneal dystrophy in Czech families maps to chromosome 20 and excludes the VSX1 gene. Invest Ophthalmol Vis Sci 46: 4480–4484. [DOI] [PubMed] [Google Scholar]
- 12. Heon E, Greenberg A, Kopp KK, Rootman D, Vincent AL, et al. (2002) VSX1: A gene for posterior polymorphous dystrophy and keratoconus. Hum Mol Genet 11: 1029–1036. [DOI] [PubMed] [Google Scholar]
- 13. Valleix S, Nedelec B, Rigaudiere F, Dighiero P, Pouliquen Y, et al. (2006) H244R VSX1 is associated with selective cone ON bipolar cell dysfunction and macular degeneration in a PPCD family. Invest Ophthalmol Vis Sci 47: 48–54. [DOI] [PubMed] [Google Scholar]
- 14. Krafchak CM, Pawar H, Moroi SE, Sugar A, Lichter PR, et al. (2005) Mutations in TCF8 cause posterior polymorphous corneal dystrophy and ectopic expression of COL4A3 by corneal endothelial cells. Am J Hum Genet 77: 694–708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Aldave AJ, Yellore VS, Yu F, Bourla N, Sonmez B, et al. (2007) Posterior polymorphous corneal dystrophy is associated with TCF8 gene mutations and abdominal hernia. Am J Med Genet A 143: 2549–2556. [DOI] [PubMed] [Google Scholar]
- 16. Vincent AL, Niederer RL, Richards A, Karolyi B, Patel DV, et al. (2009) Phenotypic characterisation and ZEB1 mutational analysis in posterior polymorphous corneal dystrophy in a New Zealand population. Mol Vis 15: 2544–2553. [PMC free article] [PubMed] [Google Scholar]
- 17. Sherwin JC, Hewitt AW, Ruddle JB, Mackey DA (2008) Genetic isolates in ophthalmic diseases. Ophthalmic Genet 29: 149–161. [DOI] [PubMed] [Google Scholar]
- 18. Reeve JP, Rannala B (2002) DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics 18: 894–895. [DOI] [PubMed] [Google Scholar]
- 19. Rannala B, Reeve JP (2001) High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence. Am J Hum Genet 69: 159–178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73: 1162–1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Marchini J, Cutler D, Patterson N, Stephens M, Eskin E, et al. (2006) A comparison of phasing algorithms for trios and unrelated individuals. Am J Hum Genet 78: 437–450. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Liskova P, Ebenezer ND, Hysi PG, Gwilliam R, El-Ashry MF, et al. (2007) Molecular analysis of the VSX1 gene in familial keratoconus. Mol Vis 13: 1887–1891. [PMC free article] [PubMed] [Google Scholar]
- 23. Liskova P, Tuft SJ, Gwilliam R, Ebenezer ND, Jirsova K, et al. (2007) Novel mutations in the ZEB1 gene identified in Czech and British patients with posterior polymorphous corneal dystrophy. Hum Mutat 28: 638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Yellore VS, Papp JC, Sobel E, Khan MA, Rayner SA, et al. (2007) Replication and refinement of linkage of posterior polymorphous corneal dystrophy to the posterior polymorphous corneal dystrophy 1 locus on chromosome 20. Genet Med 9: 228–234. [DOI] [PubMed] [Google Scholar]
- 25. Nelis M, Esko T, Magi R, Zimprich F, Zimprich A, et al. (2009) Genetic structure of Europeans: a view from the North-East. PLoS One 4: e5472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Mahtani MM, Willard HF (1998) Physical and genetic mapping of the human X chromosome centromere: repression of recombination. Genome Res 8: 100–110. [DOI] [PubMed] [Google Scholar]
- 27. Coop G, Przeworski M (2007) An evolutionary view of human recombination. Nat Rev Genet 8: 23–34. [DOI] [PubMed] [Google Scholar]
- 28. Lai IN, Yellore VS, Rayner SA, D’Silva NC, Nguyen CK, et al. (2010) The utility of next-generation sequencing in the evaluation of the posterior polymorphous corneal dystrophy 1 locus. Mol Vis 16: 2829–2838. [PMC free article] [PubMed] [Google Scholar]
- 29. Vissing H, Meyer WK, Aagaard L, Tommerup N, Thiesen HJ (1995) Repression of transcriptional activity by heterologous KRAB domains present in zinc finger proteins. FEBS Lett 369: 153–157. [DOI] [PubMed] [Google Scholar]
- 30. Gottsch JD, Seitzman GD, Margulies EH, Bowers AL, Michels AJ, et al. (2003) Gene expression in donor corneal endothelium. Arch Ophthalmol 121: 252–258. [DOI] [PubMed] [Google Scholar]
- 31. Hosseini SM, Herd S, Vincent AL, Heon E (2008) Genetic analysis of chromosome 20-related posterior polymorphous corneal dystrophy: genetic heterogeneity and exclusion of three candidate genes. Mol Vis 14: 71–80. [PMC free article] [PubMed] [Google Scholar]
- 32. Liskova P, Filipec M, Merjava S, Jirsova K, Tuft SJ (2010) Variable ocular phenotypes of posterior polymorphous corneal dystrophy caused by mutations in the ZEB1 gene. Ophthalmic Genet 31: 230–234. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.